Autopsy report · NCT00594230
LBH589 in Refractory Myelodysplastic Syndromes (MDS)
Cause of deathFutility
“Per protocol, the results of a planned interim analysis demonstrated insufficient efficacy and led to early termination of the study.”
Life of this trial
- Ran for about 3 years 2 months before it stopped.
- 26 participants enrolled.
- Results were posted on the registry 1 year 9 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- SCRI Development Innovations, LLC
- Sponsor type
- University, hospital or other
- Conditions
- Myelodysplastic Syndromes (MDS)
- Interventions
- Panobinostat
- Participants
- 26
- Sites
- 7
- Countries
- United States
Trials that died the same way
- A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
“Lack of efficacy determined at interim analysis” - Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
“The study was terminated based on the results of a planned interim analysis that showed futility of efficacy.” - A Pilot Study of Candesartan as a Treatment for Cocaine Dependence
“Results of interim efficacy analysis showed results were not promising.” - Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer
“Interim analysis determined the study did not meet criteria to proceed” - Study of Pemetrexed for Second-Line Pancreas Cancer
“At interim analysis the study did not meet the response criteria to continue”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.